Global Hyaluronic Acid for Osteoarthritis Market Size, Share & Trends Analysis Report, By Application (Knee, Hip, Ankle, and Others), By Product (Single-Injection, Three-Injection, and Five Injection), Forecast (2022-2028)

The global hyaluronic acid for osteoarthritis market is anticipated to grow at a significant CAGR of nearly 7.5% during the forecast period (2022-2028). Hyaluronic acid injections have proven to be effective in reducing and relieving inflammation caused by wearing of the cartilage and bone in osteoarthritic joints. The injected gel further supports in restoring lubrication and stimulates the growth of new cartilage and bone tissue in these joints. As per the Osteoarthritis Research Society International (OARSI), in the US, both corticosteroids and hyaluronic acid injections can be used for the treatment of osteoarthritis. The market growth is driven by the increasing prevalence of arthritis and the surge in number of sports injuries. As per the Arthritis Foundation, in the US, nearly 54.4 million adults (22.7% of all adults) had doctor-diagnosed arthritis during the period, 2013-2015. By 2040, an estimated adult aged 18 years and older with doctor-diagnosed arthritis will be 78.4 million (25.9% of the estimated total adult population) in the US. Osteoarthritis is the most common form of arthritis.
Some key players operating in the market include Anika Therapeutics, Inc., Seikagaku Corp., and Smith & Nephew plc, among others. These players are eyeing on strengthening their position in the market by adopting various strategies as mergers and acquisitions, partnerships, collaborations, new product launch and development in the existing product portfolio, and so on. For instance, in April 2020, JTA-004, a plasma protein solution supplemented with hyaluronic acid developed in a single intra-articular injection by Bone Therapeutics S.A., had entered phase 3 clinical trials for the treatment of knee osteoarthritis. Further, in December 2019, Fidia Pharma US Inc. a subsidiary of the Fidia Pharma introduced intra-articular Hyaluronic acid injections under the brand name TRILURON, for the treatment of pain in knee osteoarthritis resistant to traditional non-pharmacologic therapy and simple analgesics.

(Get 15% Discount on Buying this Report)
Get Sample Copy of hyaluronic acid for osteoarthritis market at:
https://orionmarketreports.com/request-sample/?id=94075&submit=Request+Sample%0D%0A

Market Coverage
The market number available for – 2021-2028
Base year- 2021
Forecast period- 2022-2028

Segment Covered-
By Application
By Product

Regions covered-
North America
Europe
Asia-Pacific
Rest of the World

Top Major Key Player:
Anika Therapeutics, Inc., Seikagaku Corp., and Smith & Nephew plc, among others.

A full report of hyaluronic acid for osteoarthritis market is available at:
https://orionmarketreports.com/hyaluronic-acid-for-osteoarthritis-market/94075/

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How are players addressing challenges to sustain growth?
Where is the investment opportunity?

Global Hyaluronic Acid for Osteoarthritis Market Report by Segment
By Application
Knee
Hip
Ankle
Others
By Product
Single-Injection
Three-Injection
Five-Injection

About Us:

Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.

Media Contact:

Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404